Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 16/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.38 |
| ▸ | FLT3 | P36888 | 3/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19269919 | 0.89 | FLT3 (0.38) | PIM1PIM2FLT3IRAK4PIK3CG | |
| SCHEMBL17625382 | 0.82 | PRKAB2 (0.34) | — | |
| SCHEMBL17625386 | 0.80 | PRKAB2 (0.33) | FLT3 | |
| SCHEMBL17621254 | 0.78 | PIM1 (0.47) | PIM1PIM2RET | |
| SCHEMBL19269809 | 0.77 | PIM1 (0.41) | PIM1PIM2IRAK4RET | |
| SCHEMBL17464320 | 0.76 | RET (0.38) | PIM1PIM2RET | |
| SCHEMBL17625392 | 0.74 | PRKAB2 (0.38) | IRAK4 | |
| SCHEMBL16154316 | 0.74 | DUT (0.38) | PIM1PIM2RET | |
| SCHEMBL31462308 | 0.73 | PIM1 (0.59) | PIM1PIM2FLT3IRAK4PIK3CG | |
| SCHEMBL31462314 | 0.73 | IRAK4 (0.54) | PIM1PIM2FLT3IRAK4PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377772-B2 | Macrocyclic LRRK2 kinase inhibitors | ONCODESIGN S.A. (FR) | 2019-08-13 | — | — | US | disclosed |
| EP-3194405-B1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN SA (FR) | 2018-12-26 | — | — | EP | disclosed |
| US-20170240565-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377772-B2 | Macrocyclic LRRK2 kinase inhibitors | LRRK2, PINK1, PARK7 | PIM1 700/4885PIM2 460/4885FLT3 1154/4885 |
| US-20170240565-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PINK1, PARK7 | PIM1 700/4885PIM2 460/4885FLT3 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.